Vaccines against malaria - an update (Q36933780)

17 August 2017

1 reference

title

Vaccines against malaria - an update (English)

1 reference

17 August 2017

0 references

1 reference

Kai Matuschewski

1

0 references

author name string

Ann-Kristin Mueller

series ordinal

2

1 reference

PubMed ID

17824954

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

274

1 reference

17 August 2017

18

1 reference

17 August 2017

4680-4687

1 reference

Getting infectious: formation and maturation of Plasmodium sporozoites in the Anopheles vector

17 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

The silent path to thousands of merozoites: the Plasmodium liver stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

The chequered history of malaria control: are new and better tools the ultimate answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Progress and challenges for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Vaccine-induced immunity to malaria parasites and the need for novel strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Vaccine development against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Progress towards the development of malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Gamma-globulin and acquired immunity to human malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Clinical features and pathogenesis of severe malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

21 January 2018

RTS,S/AS02A for malaria

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Antigenic variation at the infected red cell surface in malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Evidence for the involvement of VAR2CSA in pregnancy-associated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Maternal antibodies block malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Transcriptome of axenic liver stages of Plasmodium yoelii

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Restricted or absent immune responses in human populations to plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2007.05998.X

10.1111/J.1742-4658.2007.05998.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17824954